Senescence and pre-malignancy: how do tumors progress?
- PMID: 21982725
- DOI: 10.1016/j.semcancer.2011.09.013
Senescence and pre-malignancy: how do tumors progress?
Abstract
Cellular senescence is a tumor suppressor response that has been observed both in vitro and in vivo, and features of senescence have been documented in various human premalignant lesions, including melanoma, colon and lung adenoma, prostatic intraepithelial neoplasia, and others. The fact that a subset of these lesions eventually progress to malignant invasive tumors suggests that premalignant cells can either bypass or escape the senescent response. Much work has been done to understand the mechanisms underlying such progression, but it remains unclear whether tumors progress by evasion of senescence induction, or by disruption of senescence maintenance, or whether both mechanisms can occur in human cancer development. This review presents the current evidence for mechanisms of senescence evasion and reversion, and discusses what has been learnt about this process using in vitro and in vivo experimental systems. As we learn more about the key signaling effectors of senescence, the hope is that appropriate targets will be identified for preservation and/or re-induction of senescence in human tumors. Such knowledge may also find application in better estimation of risks of cancer progression in individual premalignant lesions, which will lead to more accurate allocation of appropriate treatment options for such patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Cellular senescence in oral cancer and precancer and treatment implications: a review.Acta Oncol. 2008;47(8):1464-74. doi: 10.1080/02841860802183612. Acta Oncol. 2008. PMID: 18607883 Review.
-
Tumour biology: senescence in premalignant tumours.Nature. 2005 Aug 4;436(7051):642. doi: 10.1038/436642a. Nature. 2005. PMID: 16079833
-
Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.Clin Cancer Res. 2006 Mar 1;12(5):1479-86. doi: 10.1158/1078-0432.CCR-05-1519. Clin Cancer Res. 2006. PMID: 16533771
-
Cancer, aging and cellular senescence.In Vivo. 2000 Jan-Feb;14(1):183-8. In Vivo. 2000. PMID: 10757076 Review.
-
Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.Cancer Res. 2005 Apr 1;65(7):2795-803. doi: 10.1158/0008-5472.CAN-04-1270. Cancer Res. 2005. PMID: 15805280
Cited by
-
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence".Cancer Metastasis Rev. 2013 Dec;32(3-4):403-21. doi: 10.1007/s10555-013-9431-y. Cancer Metastasis Rev. 2013. PMID: 23615877 Free PMC article. Review.
-
STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.Cell Cycle. 2017 Feb 16;16(4):319-334. doi: 10.1080/15384101.2016.1259037. Epub 2016 Nov 28. Cell Cycle. 2017. PMID: 27892764 Free PMC article.
-
Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars.Cell Genom. 2023 Apr 5;3(4):100293. doi: 10.1016/j.xgen.2023.100293. eCollection 2023 Apr 12. Cell Genom. 2023. PMID: 37082139 Free PMC article.
-
Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation.Blood. 2014 Jun 26;123(26):4089-100. doi: 10.1182/blood-2013-11-539411. Epub 2014 Apr 15. Blood. 2014. PMID: 24735967 Free PMC article.
-
The fate of chemoresistance in triple negative breast cancer (TNBC).BBA Clin. 2015 Mar 12;3:257-75. doi: 10.1016/j.bbacli.2015.03.003. eCollection 2015 Jun. BBA Clin. 2015. PMID: 26676166 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
